Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6048653 | 0.89 | TSHR (0.42) | TSHRPTPN1LMNAHCAR2MEN1 | |
| SCHEMBL7503891 | 0.85 | MAPT (0.33) | MAPT | |
| SCHEMBL31462323 | 0.83 | LMNA (0.37) | TSHRPTPN1LMNAHCAR2MEN1 | |
| SCHEMBL3531184 | 0.83 | MAPT (0.34) | MEN1KMT2AMAPT | |
| SCHEMBL6048743 | 0.83 | CTSK (0.33) | — | |
| SCHEMBL27432594 | 0.83 | TSHR (0.37) | TSHRPTPN1LMNAHCAR2MEN1 | |
| SCHEMBL8404113 | 0.80 | CHRM1 (0.34) | — | |
| SCHEMBL28363839 | 0.79 | MEN1 (0.43) | TSHRPTPN1LMNAMEN1KMT2A | |
| Bicarbonate SCHEMBL28369373 | 0.79 | MMP1 (0.34) | TSHRPTPN1LMNAMEN1KMT2A | |
| SCHEMBL27792243 | 0.78 | TSHR (0.37) | TSHRPTPN1LMNAHCAR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115449900-B | Texturing treating agent, preparation method thereof and method for texturing monocrystalline silicon wafer | 浙江奥首材料科技有限公司 | 2023-11-21 | — | — | CN | claimed |
| CN-115449900-A | Texturing treating agent, preparation method thereof and method for texturing monocrystalline silicon wafer | 浙江奥首材料科技有限公司 | 2022-12-09 | — | — | CN | claimed |
| CN-114805647-A | Catalyst composition for olefin polymerization and application thereof | 北京肯佰恩科技发展有限公司 | 2022-07-29 | — | — | CN | claimed |
| US-20240191594-A1 | Cement Top Jobs In Wellbore Annuli Using Expandable Compositions | CHEVRON U.S.A. INC. | 2024-06-13 | — | — | US | disclosed |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | CAYMAN CHEMICAL COMPANY, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20240026206-A1 | METHODS OF USING EXPANDABLE POLYMER GROUT FOR PLUG AND ABANDONMENT APPLICATIONS | CHEVRON AUSTRALIA PTY LTD (AU) | 2024-01-25 | — | — | US | disclosed |
| US-20240026749-A1 | DEPLOYMENT METHODS FOR EXPANDABLE POLYMER GROUT FOR PLUG AND ABANDONMENT APPLICATIONS | CHEVRON AUSTRALIA PTY LTD (AU) | 2024-01-25 | — | — | US | disclosed |
| CN-115449900-B | Texturing treating agent, preparation method thereof and method for texturing monocrystalline silicon wafer | 浙江奥首材料科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11390060-B2 | Surface treatment to enhance bonding of composite materials | CYTEC INDUSTRIES INC. (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2022132552-A1 | DEPLOYMENT METHODS FOR EXPANDABLE POLYMER GROUT FOR PLUG AND ABANDONMENT APPLICATIONS | CHEVRON U.S.A. INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-0834519-A1 | CATALYST FOR POLYOLEFIN PRODUCTION AND PROCESS FOR PRODUCING POLYOLEFIN | Japan Polyolefins Co., Ltd. (JP) | 1998-04-08 | — | — | EP | disclosed |
| EP-0739907-A1 | An olefin polymerization catalyst and a polyolefin production method | TOKUYAMA CORPORATION (JP) | 1996-10-30 | — | — | EP | disclosed |
| US-5482939-A | ANTI-PLATELET ACTIVATING FACTOR ACTIVITIES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-09 | — | — | US | disclosed |
| US-5389633-A | ANTIASTHMATIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-02-14 | — | — | US | disclosed |
| EP-0562439-A1 | Triazolopyridazines as antioasthmatics | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0361365-A1 | Aminobenzoic and aminocyclohexane-carboylic acid compounds, compositions, and their method of use | E.R. SQUIBB & SONS, INC. (US) | 1990-04-04 | — | — | EP | disclosed |
| EP-0321218-A2 | Process for producing polypropylene and stretched polypropylene film | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-06-21 | — | — | EP | disclosed |
| US-4824981-A | REACTING MALONATES WITH TRIALKYLSILANES, ALKALI METAL AND DIALKYLMALONIC ACID; PURITY | DOW CORNING CORPORATION (US) | 1989-04-25 | — | — | US | disclosed |
| EP-0298363-A2 | A process to produce silyl ketene acetals | DOW CORNING CORPORATION (US) | 1989-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050318-A1 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | PTGER4, PTGER1, PTGER3 | TSHR 554/4885PTPN1 4182/4885LMNA 2913/4885 |
| US-11884624-B2 | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions | PTGER4, PTGER1, PTGER3 | TSHR 554/4885PTPN1 4182/4885LMNA 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.